US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
AU677577B2
(en)
*
|
1992-02-21 |
1997-05-01 |
Alcon Laboratories, Inc. |
Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
WO1994006411A1
(en)
*
|
1992-09-17 |
1994-03-31 |
Alcon Laboratories, Inc. |
Topical carbonic anhydrase inhibitor composition
|
SE9301877D0
(en)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
IN SITU GEL FOR THERAPEUTIC USE
|
JP2742333B2
(en)
*
|
1994-05-06 |
1998-04-22 |
アルコン ラボラトリーズ,インコーポレイテッド |
Use of vitamin E tocopheryl derivatives in ophthalmic compositions
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
AU704938B2
(en)
*
|
1995-11-17 |
1999-05-06 |
Alcon Laboratories, Inc. |
Combination therapy for treating glaucoma
|
FR2754712B1
(en)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
OPHTHALMIC COMPOSITIONS
|
CH690814A5
(en)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Compositions for topical use containing sulphates polysaccharides.
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
WO2000038663A2
(en)
|
1998-12-24 |
2000-07-06 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
AU2183800A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Prostaglandin e agonists for treatment of dry eye
|
DK1616869T3
(en)
|
1999-01-25 |
2012-05-07 |
Nat Jewish Health |
Substituted porphyrins and their therapeutic use
|
PT1225898E
(en)
|
1999-11-01 |
2003-10-31 |
Alcon Inc |
PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTIBIOTIC PHARMACO OF FLUOROQUINOLONE AND XANTANA GUM
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
PL356092A1
(en)
|
1999-11-09 |
2004-06-14 |
Alcon Inc. |
Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
|
PT1228030E
(en)
|
1999-11-09 |
2005-08-31 |
Alcon Inc |
BENZENOID DERIVATIVES OF 15-HYDROXYETHYLATE-ACETATE ACID AND METHODS FOR THEIR USE IN THE TREATMENT OF DRY EYE PERTURBACTIONS
|
AU1226001A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
JP2003514782A
(en)
|
1999-11-09 |
2003-04-22 |
アルコン,インコーポレイテッド |
Lipoxin A4 and analogs thereof for treatment of dry eye
|
DE60007548T2
(en)
|
1999-11-09 |
2004-06-17 |
Alcon, Inc. |
OMEGA CHAIN-MODIFIED HYDROXYEICOSATETRAIC ACID DERIVATIVES USED IN THE TREATMENT OF THE "DRY EYE" DISEASE
|
ATE265996T1
(en)
|
1999-11-09 |
2004-05-15 |
Alcon Inc |
TRI-HETEROATOM-SUBSTITUTED AND TWO-CARBON HOMOLOGUE OF 15-HETE AND METHOD OF USE
|
AU775189B2
(en)
|
1999-11-09 |
2004-07-22 |
Alcon Inc. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
CA2386636A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon, Inc. |
15-hydroxyeicosatetraenoic acid-related compounds and methods of use
|
WO2001034550A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
AU1101301A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
WO2001034549A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
|
WO2001046134A1
(en)
|
1999-12-22 |
2001-06-28 |
Alcon Universal Ltd. |
6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
|
AU2001270593A1
(en)
|
2000-07-28 |
2002-02-13 |
Alcon Universal Ltd. |
Pharmaceutical compositions containing tobramycin and xanthan gum
|
AR031135A1
(en)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
TOPIC ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF OCULAR INFECTIONS
|
US7060297B2
(en)
|
2000-11-06 |
2006-06-13 |
Alcon, Inc. |
Carrageenan viscoelastics for ocular surgery
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
CA2447883A1
(en)
|
2001-05-21 |
2002-11-28 |
Alcon, Inc. |
Use of nf-kappa-b inhibitors to treat dry eye disorders
|
EP1392322A1
(en)
*
|
2001-05-21 |
2004-03-03 |
Alcon, Inc. |
Method of treating dry eye disorders
|
MXPA03010634A
(en)
|
2001-05-21 |
2004-03-09 |
Alcon Inc |
Use of proteasome inhibitors to treat dry eye disorders.
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
AU2002312194B8
(en)
*
|
2001-06-01 |
2008-05-15 |
Aeolus Sciences, Inc. |
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
US6750250B1
(en)
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
CA2464736A1
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
MXPA04008171A
(en)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Ophthalmic formulation with gum system.
|
US20040019012A1
(en)
*
|
2002-02-22 |
2004-01-29 |
Singh Satish K. |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
|
SI1534286T1
(en)
|
2002-07-29 |
2010-04-30 |
Rigel Pharmaceuticals Inc |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
US20040248794A1
(en)
*
|
2002-12-20 |
2004-12-09 |
Yanni John M. |
Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
|
ES2365223T3
(en)
|
2003-08-07 |
2011-09-26 |
Rigel Pharmaceuticals, Inc. |
2,4-PYRIMIDINDIAMINE COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS.
|
EP2404606A1
(en)
*
|
2003-08-21 |
2012-01-11 |
Sucampo AG |
Ophthalmic compositions comprising a prostaglandin and a viscosity agent
|
WO2006034296A2
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc. |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
JP2008513495A
(en)
*
|
2004-09-17 |
2008-05-01 |
コメンティス,インコーポレーテッド |
Bicyclic compounds that inhibit beta-secretase activity and methods of use thereof
|
WO2006068760A2
(en)
*
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
JP2008535863A
(en)
*
|
2005-04-08 |
2008-09-04 |
コメンティス,インコーポレーテッド |
Compounds that inhibit β-secretase activity and methods of use thereof
|
EP1991532B1
(en)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
WO2008005457A2
(en)
|
2006-06-30 |
2008-01-10 |
Sunesis Pharmaceuticals |
Pyridinonyl pdk1 inhibitors
|
ES2380551T3
(en)
|
2006-11-21 |
2012-05-16 |
Rigel Pharmaceuticals, Inc. |
Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
|
KR20080076667A
(en)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
Thixotropic pharmaceutical compositions
|
EP2170283B1
(en)
|
2007-06-22 |
2019-01-09 |
Board of Regents, The University of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
KR20100051668A
(en)
*
|
2007-07-26 |
2010-05-17 |
코멘티스, 인코포레이티드 |
Isophthalamide derivatives inhibiting beta-secretase activity
|
CA2699787A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Comentis, Inc. |
(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
|
EP2234608A2
(en)
|
2007-12-11 |
2010-10-06 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
KR20100133980A
(en)
*
|
2008-03-07 |
2010-12-22 |
썬 파마 어드밴스트 리서치 컴패니 리미티드 |
Opthalmic composition
|
EP2732817B1
(en)
|
2008-05-23 |
2016-08-24 |
National Jewish Health |
A compound for use in treating injury associated with exposure to phosgene or chlorine gas
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
WO2010011684A2
(en)
*
|
2008-07-21 |
2010-01-28 |
The Regents Of The University Of California |
Prodrug and fluoregenic compositions and methods for using the same
|
CN102264728B
(en)
|
2008-09-15 |
2015-02-04 |
加利福尼亚大学董事会 |
Methods and compositions for modulating IRE1, SRC, and ABL activity
|
WO2010078369A2
(en)
|
2008-12-30 |
2010-07-08 |
Rigel Pharmaceuticals, Inc. |
Pyrimidinediamine kinase inhibitors
|
NZ594323A
(en)
|
2009-01-23 |
2013-05-31 |
Rigel Pharmaceuticals Inc |
Compositions and methods for inhibition of the jak pathway
|
CN102405044A
(en)
|
2009-02-06 |
2012-04-04 |
南加利福尼亚大学 |
Therapeutic compositions comprising monoterpenes
|
MX2011008647A
(en)
*
|
2009-02-20 |
2011-10-28 |
Micro Labs Ltd |
Storage stable prostaglandin product.
|
EP2459195A1
(en)
|
2009-07-28 |
2012-06-06 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
CA2771190C
(en)
|
2009-08-17 |
2020-01-21 |
Memorial Sloan-Kettering Cancer Center |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
CN107011330B
(en)
|
2009-09-04 |
2020-07-03 |
比奥根Ma公司 |
Bruton's tyrosine kinase inhibitors
|
EP2485589A4
(en)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
Heteroaryl btk inhibitors
|
AU2010303567B2
(en)
|
2009-10-06 |
2016-06-09 |
Millennium Pharmaceuticals, Inc |
Heterocyclic compounds useful as PDK1 inhibitors
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
PT2853262T
(en)
|
2009-10-26 |
2017-01-31 |
Sephoris Pharmaceuticals Llc |
Treatment of sunburn using analgesics and antihistamines
|
CN102711765A
(en)
|
2009-11-16 |
2012-10-03 |
加利福尼亚大学董事会 |
Kinase inhibitors
|
SG181561A1
(en)
|
2009-12-10 |
2012-07-30 |
Univ California |
Amyloid binding agents
|
CN102892289B
(en)
|
2010-03-03 |
2015-03-25 |
尼昂克技术公司 |
Pharmaceutical compositions comprising monoterpenes
|
KR102113960B1
(en)
|
2010-03-30 |
2020-05-21 |
베르선 코포레이션 |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
RS55010B1
(en)
|
2010-04-24 |
2016-11-30 |
Viamet Pharmaceuticals Inc |
Metalloenzyme inhibitor compounds
|
KR101937495B1
(en)
|
2010-07-28 |
2019-01-10 |
리겔 파마슈티칼스, 인크. |
Compositions and methods for inhibition of the jak pathway
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
EP2883543B1
(en)
|
2010-08-27 |
2016-11-16 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising perillyl alcohol carbamates
|
CA2816088A1
(en)
|
2010-10-28 |
2012-05-03 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
US9273028B2
(en)
|
2010-10-29 |
2016-03-01 |
Biogen Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
US8389543B2
(en)
|
2010-11-13 |
2013-03-05 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
BR112013014484A2
(en)
|
2010-12-13 |
2016-07-19 |
Viamet Pharmaceuticals Inc |
metalloenzyme inhibitor compounds
|
BR112013015107B1
(en)
|
2010-12-17 |
2022-03-22 |
Neonc Technologies Inc. |
Pharmaceutical composition, use of an isoperyl alcohol or an isoperyl alcohol carbamate and process for producing an isoperyl alcohol carbamate
|
BR112013020719B1
(en)
|
2011-02-14 |
2018-04-17 |
Allergan, Inc. |
BIMATOPROST ESTER TYPE AND METHOD DERIVATIVE COMPOSITIONS
|
EP2678297A2
(en)
|
2011-02-25 |
2014-01-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chrysophaentin analogs that inhibit ftsz protein
|
WO2012149416A2
(en)
|
2011-04-28 |
2012-11-01 |
University Of Southern California |
Human myeloid derived suppressor cell cancer markers
|
CA2836449C
(en)
|
2011-05-17 |
2021-04-27 |
The Regents Of The University Of California |
Kinase inhibitors
|
SI2710005T1
(en)
|
2011-05-17 |
2017-03-31 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
JP2014521594A
(en)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
Long duration dual hormone conjugate
|
KR101912850B1
(en)
|
2011-06-19 |
2018-10-30 |
비아멧 파마슈티컬즈(엔씨), 인코포레이티드 |
Metalloenzyme inhibitor compounds
|
EA024789B1
(en)
|
2011-06-19 |
2016-10-31 |
Ваймет Фармасьютикалс, Инк. |
Metalloenzyme inhibitor compounds
|
EP2723730A4
(en)
|
2011-06-23 |
2014-12-31 |
Viamet Pharmaceuticals Inc |
Metalloenzyme inhibitor compounds
|
EP2726097A4
(en)
|
2011-07-01 |
2015-03-11 |
Univ California |
Herpes virus vaccine and methods of use
|
MX370814B
(en)
|
2011-09-02 |
2020-01-08 |
Univ California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof.
|
WO2013063492A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
EP2788343B1
(en)
|
2011-12-11 |
2018-02-28 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyme inhibitor compounds
|
BR112014017751B1
(en)
|
2012-01-20 |
2021-12-07 |
Mycovia Pharmaceuticals, Inc |
METALLOENZYME INHIBITOR COMPOUNDS, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND USE OF SUCH COMPOUNDS
|
EP2828241B1
(en)
|
2012-03-23 |
2018-09-12 |
Mateon Therapeutics, Inc. |
Compositions and methods for inhibition of cathepsins
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
US20130310340A1
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
WO2013185082A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Inhibitors of bruton's tyrosine kinase
|
AR091273A1
(en)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
PYRIMIDINYL TIROSINE KINASE INHIBITORS
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
CN104684904B
(en)
|
2012-08-27 |
2017-10-13 |
阿勒根公司 |
Mitigate central cornea by using the hydrophilic ester prodrug of β chlorine pentamethylene to thicken
|
SI3181567T1
(en)
|
2012-09-10 |
2019-09-30 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
EP2900673A4
(en)
|
2012-09-26 |
2016-10-19 |
Univ California |
Modulation of ire1
|
AU2013334707B2
(en)
|
2012-10-22 |
2018-02-22 |
City Of Hope |
ETP derivatives
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
NZ710444A
(en)
|
2013-02-11 |
2020-08-28 |
Univ California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
WO2014165263A1
(en)
|
2013-03-12 |
2014-10-09 |
The Regents Of The University Of California, A California Corporation |
Gamma-secretase modulators
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
CN105283456B
(en)
|
2013-03-14 |
2018-12-18 |
希望之城 |
The bromo- indigo red of 5-
|
AU2014236356A1
(en)
|
2013-03-14 |
2015-09-24 |
The Regents Of The University Of California |
Thiosaccharide mucolytic agents
|
EP2968270A4
(en)
|
2013-03-14 |
2016-08-17 |
Univ California |
Modulation of k2p channels
|
AU2014228307A1
(en)
|
2013-03-15 |
2015-09-10 |
Allergan, Inc. |
Bimatoprost for enhancement of leptin production
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
JP6806562B2
(en)
|
2013-03-15 |
2021-01-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Regulator of the eIF2α pathway
|
EP2968297B1
(en)
|
2013-03-15 |
2018-09-26 |
Verseon Corporation |
Multisubstituted aromatic compounds as serine protease inhibitors
|
UY35464A
(en)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
KRAS G12C COVALENT INHIBITORS.
|
WO2014143643A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California, A California Corporation |
Acyclic nucleoside phosphonate diesters
|
ES2791749T3
(en)
|
2013-03-15 |
2020-11-05 |
Verseon Corp |
Halogenopyrazoles as thrombin inhibitors
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
CA2949048A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
WO2015009742A2
(en)
|
2013-07-15 |
2015-01-22 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
EP3636264A1
(en)
|
2013-08-19 |
2020-04-15 |
The Regents of the University of California |
Compounds and methods for treating an epileptic disorder
|
WO2015026935A2
(en)
|
2013-08-20 |
2015-02-26 |
City Of Hope |
Hdac8 inhibitors for treating cancer
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
JO3805B1
(en)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c
|
AU2014362231B2
(en)
|
2013-12-11 |
2019-04-04 |
Biogen Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
ES2713196T3
(en)
|
2013-12-11 |
2019-05-20 |
Biogen Ma Inc |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
AU2014386214B2
(en)
|
2013-12-23 |
2020-05-21 |
Memorial Sloan-Kettering Cancer Center |
Methods and reagents for radiolabeling
|
PT2898888T
(en)
*
|
2014-01-22 |
2019-07-16 |
Visufarma B V |
Composition comprising iota-carrageenan against viral conjunctivitis
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
US10167286B2
(en)
|
2014-02-11 |
2019-01-01 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
EP3104857A4
(en)
|
2014-02-14 |
2017-10-11 |
The Regents of The University of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
KR20160124835A
(en)
|
2014-02-20 |
2016-10-28 |
알러간, 인코포레이티드 |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
MX2016010754A
(en)
|
2014-02-21 |
2017-03-03 |
Principia Biopharma Inc |
Salts and solid form of a btk inhibitor.
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
EP3128842B1
(en)
|
2014-03-26 |
2023-07-26 |
City of Hope |
Treatment of brca1-defective cancer or resistant cancers
|
EP3988540A1
(en)
|
2014-04-07 |
2022-04-27 |
The Regents of the University of California |
Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
|
SG11201609336PA
(en)
|
2014-05-13 |
2016-12-29 |
Sloan Kettering Inst Cancer |
Hsp70 modulators and methods for making and using the same
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
CN107073066B
(en)
|
2014-09-11 |
2021-09-17 |
加利福尼亚大学董事会 |
mTORC1 inhibitors
|
EA036391B1
(en)
|
2014-09-15 |
2020-11-05 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Nucleotide analogs
|
WO2016044662A1
(en)
|
2014-09-17 |
2016-03-24 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
JO3556B1
(en)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
Combination therapies for treatment of cancer
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
AR102094A1
(en)
|
2014-09-25 |
2017-02-01 |
Araxes Pharma Llc |
KRAS PROTEIN INHIBITORS WITH A G12C MUTATION
|
ES2757798T3
(en)
|
2014-10-02 |
2020-04-30 |
Allergan Inc |
Gamma-lactam ester prodrugs and their use
|
MA41197B1
(en)
|
2014-12-18 |
2021-01-29 |
Principia Biopharma Inc |
Treatment of pemphigus
|
EP3244907B1
(en)
|
2015-01-13 |
2020-02-19 |
City of Hope |
Ctla4-binding protein peptide-linker masks
|
CN107427550B
(en)
|
2015-01-16 |
2021-10-08 |
希望之城 |
Cell penetrating antibodies
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016130800A2
(en)
|
2015-02-12 |
2016-08-18 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising perillyl alcohol derivatives
|
WO2016138138A1
(en)
|
2015-02-25 |
2016-09-01 |
The Regents Of The University Of California |
5ht agonists for treating disorders
|
WO2016138532A1
(en)
|
2015-02-27 |
2016-09-01 |
Verseon Corporation |
Substituted pyrazole compounds as serine protease inhibitors
|
US11072592B2
(en)
|
2015-02-27 |
2021-07-27 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvenation
|
IL254007B1
(en)
|
2015-02-27 |
2024-04-01 |
Curtana Pharmaceuticals Inc |
Inhibition of olig2 activity
|
CA2981504C
(en)
|
2015-03-30 |
2023-10-24 |
City Of Hope |
Mechanically interlocking complexes
|
EA201792214A1
(en)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
COMPOUNDS OF SUBSTITUTE QUINAZOLINE
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
AU2016247858B2
(en)
|
2015-04-17 |
2020-10-15 |
Ludwig Institute For Cancer Research Ltd. |
PLK4 inhibitors
|
EP3286214B1
(en)
|
2015-04-24 |
2023-12-06 |
The Regents of the University of California |
Modulators of ror1-ror2 binding
|
EP3842448A1
(en)
|
2015-05-15 |
2021-06-30 |
City of Hope |
Chimeric antigen receptor compositions
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
US20180282310A1
(en)
|
2015-06-10 |
2018-10-04 |
Biogen Ma Inc. |
Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
|
WO2016201169A1
(en)
|
2015-06-10 |
2016-12-15 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
EP3313839A1
(en)
|
2015-06-24 |
2018-05-02 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
CA2991052A1
(en)
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
US10065946B2
(en)
|
2015-08-04 |
2018-09-04 |
Rigel Pharmaceuticals, Inc. |
Benzazole compounds and methods for making and using the compounds
|
TW201718023A
(en)
|
2015-08-06 |
2017-06-01 |
世代好公司 |
Cell penetrating protein-antibody conjugates and methods of use
|
WO2017040693A1
(en)
|
2015-08-31 |
2017-03-09 |
The Regents Of The University Of California |
Broad spectrum antiviral compounds and uses thereof
|
WO2017040982A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of California |
Her3 ligands and uses thereof
|
JP6933644B2
(en)
|
2015-09-04 |
2021-09-08 |
シティ・オブ・ホープCity of Hope |
Androgen receptor antagonist
|
US11253521B2
(en)
|
2015-09-25 |
2022-02-22 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
JP7038045B2
(en)
|
2015-10-15 |
2022-03-17 |
シティ・オブ・ホープ |
Compounds and compositions containing phosphorothioated oligodeoxynucleotides, and methods of use thereof.
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
BR112018008025A2
(en)
|
2015-10-23 |
2018-10-23 |
Sunesis Pharmaceuticals, Inc. |
heterocyclic pdk1 inhibitors for use in cancer treatment
|
BR112018008103A2
(en)
|
2015-10-23 |
2018-11-06 |
Erx Pharmaceuticals, Inc. |
celastrol analogs
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
KR20180081596A
(en)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
Substituted quinazoline compounds comprising substituted heterocyclic groups and methods for their use
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
CN108603037B
(en)
|
2015-12-10 |
2020-11-17 |
希望之城 |
Cell penetrating cyanine conjugated antibodies
|
JP6938510B2
(en)
|
2015-12-24 |
2021-09-22 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
CFTR regulator and how to use it
|
JP6938509B2
(en)
|
2015-12-24 |
2021-09-22 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
CFTR regulator and how to use it
|
EP3397629B1
(en)
|
2015-12-30 |
2023-04-19 |
NQP 1598, Ltd. |
Metalloenzyme inhibitor compounds
|
CN108697690B
(en)
|
2016-01-05 |
2022-01-14 |
加利福尼亚大学董事会 |
Benzothiazole amphiphiles
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
BR112018068798A2
(en)
|
2016-03-17 |
2019-01-22 |
Univ California |
compositions and methods for treating parasitic diseases
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
WO2017189613A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
CA3022432A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
TW201808914A
(en)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
Modulators of the integrated stress pathway
|
TWI763668B
(en)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
Modulators of the integrated stress pathway
|
PE20190119A1
(en)
|
2016-05-12 |
2019-01-17 |
Anacor Pharmaceuticals Inc |
OXABOROL ESTERS AND THEIR USES
|
EP3463342B1
(en)
|
2016-05-26 |
2023-09-06 |
The Regents of The University of California |
Estrogen receptor modulator combinations
|
US10710983B2
(en)
|
2016-06-27 |
2020-07-14 |
Rigel Pharmaceuticals, Inc. |
2,4-diamino-pyrimidine compounds and method for making and using the compounds
|
EP3478273A1
(en)
|
2016-06-29 |
2019-05-08 |
Principia Biopharma Inc. |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
WO2018013609A2
(en)
|
2016-07-11 |
2018-01-18 |
The Regents The University Of California |
Synthetic melanin nanoparticles uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
MX2019000884A
(en)
|
2016-07-21 |
2019-09-04 |
Biogen Ma Inc |
Succinate forms and compositions of bruton's tyrosine kinase inhibitors.
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
CN109982710A
(en)
|
2016-09-13 |
2019-07-05 |
杰克逊实验室 |
Target the DNA demethylation of enhancing
|
US10822353B2
(en)
|
2016-09-15 |
2020-11-03 |
City Of Hope |
Dithio ETP derivatives
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
EP3532470B1
(en)
|
2016-10-26 |
2022-12-07 |
Rigel Pharmaceuticals, Inc. |
Oxazole derivatives for use as irak inhibitors and method for their preparation
|
EP3532465B1
(en)
|
2016-10-26 |
2023-03-01 |
Rigel Pharmaceuticals, Inc. |
Pyrazole amide compounds as irak inhibitors
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
EP3547836A4
(en)
|
2016-11-30 |
2020-08-05 |
Neonc Technologies Inc. |
A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
|
CA3047125A1
(en)
|
2016-12-15 |
2018-06-21 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
EP4311577A3
(en)
|
2016-12-29 |
2024-04-17 |
Ji Xing Pharmaceuticals Hong Kong Limited |
Metalloenzyme inhibitor compounds
|
WO2018125799A2
(en)
|
2016-12-29 |
2018-07-05 |
Viamet Pharmaceuticals (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
CN110382482A
(en)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
Condensed miscellaneous-Heterobicyclic compounds and its application method
|
MX2019013954A
(en)
|
2017-05-25 |
2020-08-31 |
Araxes Pharma Llc |
Covalent inhibitors of kras.
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
TW201906832A
(en)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
Compounds for cancer treatment and methods of use thereof
|
EP3641545A4
(en)
|
2017-06-21 |
2021-02-24 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
CN111032642B
(en)
|
2017-06-29 |
2023-07-18 |
里格尔药品股份有限公司 |
Kinase inhibitors and methods of making and using the same
|
US11554178B2
(en)
|
2017-06-30 |
2023-01-17 |
City Of Hope |
Compositions and methods of modulating macrophage activity
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
CN111386283A
(en)
|
2017-09-29 |
2020-07-07 |
基因泰克公司 |
Peptide antimicrobial complexes and methods of use thereof
|
US20200354452A1
(en)
|
2017-09-29 |
2020-11-12 |
City Of Hope |
Cars and bispecific antibodies for treatment of mantle cell lymphoma
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
WO2019074962A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazine compounds and methods of inhibiting tam kinases
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
UY37956A
(en)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
INTEGRATED STRESS ROAD MODULATORS
|
BR112020008825A2
(en)
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
modulators of the integrated stress pathway
|
UY37958A
(en)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
INTEGRATED STRESS ROAD MODULATORS
|
UY37957A
(en)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
INTEGRATED STRESS ROAD MODULATORS
|
BR112020008834A2
(en)
|
2017-11-02 |
2020-12-22 |
Calico Life Sciences Llc |
MODULATORS OF THE INTEGRATED STRESS ROUTE
|
BR112020008827A2
(en)
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
modulators of the integrated stress pathway
|
JP7335241B2
(en)
|
2017-11-02 |
2023-08-29 |
カリコ ライフ サイエンシーズ エルエルシー |
Modulators of integrated stress pathways
|
IL274406B2
(en)
|
2017-11-02 |
2024-04-01 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
EP3704125A1
(en)
|
2017-11-02 |
2020-09-09 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
KR20200104291A
(en)
|
2017-11-06 |
2020-09-03 |
랩트 테라퓨틱스, 인크. |
Anticancer drugs
|
WO2019113542A1
(en)
|
2017-12-07 |
2019-06-13 |
Amplyx Pharmaceuticals, Inc. |
Heterocycle substituted pyridine derivative antifungal agents
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
WO2019143730A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
CA3088526A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10683280B2
(en)
|
2018-01-26 |
2020-06-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2019157195A1
(en)
|
2018-02-08 |
2019-08-15 |
Neonc Technologies, Inc |
Methods of permeabilizing the blood brain barrier
|
CA3093802A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
EP3784233B1
(en)
|
2018-04-27 |
2024-06-05 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
AU2019262978B2
(en)
|
2018-05-01 |
2023-07-13 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
|
JP7381492B2
(en)
|
2018-05-01 |
2023-11-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
C26-linked rapamycin analogs as MTOR inhibitors
|
BR112020022420A2
(en)
|
2018-05-03 |
2021-03-02 |
Rigel Pharmaceuticals, Inc. |
compound, pharmaceutical composition, method, method for treating a disease in an individual and method for producing the compound
|
SG11202010913PA
(en)
|
2018-05-03 |
2020-12-30 |
Rigel Pharmaceuticals Inc |
Rip1 inhibitory compounds and methods for making and using the same
|
US11931345B2
(en)
|
2018-05-04 |
2024-03-19 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
|
JP2021527051A
(en)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
Pyrazolo-pyrimidine-amino-cycloalkyl compounds and their therapeutic use
|
CA3104507A1
(en)
|
2018-06-21 |
2019-12-26 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
WO2020005860A1
(en)
|
2018-06-25 |
2020-01-02 |
Amplyx Pharmaceuticals, Inc. |
Pyridine derivatives substituted by heterocyclic ring and amino group
|
CN112867503A
(en)
|
2018-08-24 |
2021-05-28 |
希望之城 |
Masked cytokine conjugates
|
TWI832295B
(en)
|
2018-10-11 |
2024-02-11 |
美商嘉來克生命科學有限責任公司 |
Prodrug modulators of the integrated stress pathway
|
WO2020092845A1
(en)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
JP2022506908A
(en)
|
2018-11-01 |
2022-01-17 |
リンク・ファーマシューティカルズ・カンパニー・リミテッド |
Tricyclic Janus kinase 1 inhibitor and its composition and method
|
CA3131894A1
(en)
|
2019-03-14 |
2020-09-17 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
US20200347043A1
(en)
|
2019-04-30 |
2020-11-05 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
US10973780B2
(en)
|
2019-05-15 |
2021-04-13 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
CA3147443A1
(en)
|
2019-08-08 |
2021-02-11 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating cytokine release syndrome
|
ES2970382T3
(en)
|
2019-08-14 |
2024-05-28 |
Rigel Pharmaceuticals Inc |
Method to block or improve cytokine release syndrome
|
AR119857A1
(en)
|
2019-08-30 |
2022-01-19 |
Rigel Pharmaceuticals Inc |
PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF AND THEIR USE FOR THE INHIBITION OF AN IRAQ PROTEIN
|
CN115279763A
(en)
|
2019-09-06 |
2022-11-01 |
里格尔药品股份有限公司 |
RIP1 inhibiting compounds and methods of making and using the same
|
TW202122397A
(en)
|
2019-09-06 |
2021-06-16 |
美商雷傑製藥公司 |
Rip1 inhibitory compounds and methods for making and using the same
|
KR20220064983A
(en)
|
2019-09-18 |
2022-05-19 |
노파르티스 아게 |
NKG2D fusion protein and uses thereof
|
US11370803B2
(en)
|
2019-09-18 |
2022-06-28 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
CN114728962A
(en)
|
2019-09-18 |
2022-07-08 |
武田药品工业有限公司 |
Plasma kallikrein inhibitors and uses thereof
|
TW202132307A
(en)
|
2019-11-07 |
2021-09-01 |
美商雷傑製藥公司 |
Heterocyclic rip1 inhibitory compounds
|
MX2022005795A
(en)
|
2019-11-13 |
2022-06-08 |
Rapt Therapeutics Inc |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof.
|
EP4077291A1
(en)
|
2019-12-18 |
2022-10-26 |
Calico Life Sciences LLC |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
MX2022014605A
(en)
|
2020-05-19 |
2022-12-16 |
Cybin Irl Ltd |
Deuterated tryptamine derivatives and methods of use.
|
EP4200290A1
(en)
|
2020-08-18 |
2023-06-28 |
Cybin IRL Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2022094409A1
(en)
|
2020-11-02 |
2022-05-05 |
Trethera Corporation |
Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
|
JP2023551145A
(en)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル,インク. |
Complexing agent salt formulations of pharmaceutical compounds
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
TW202300490A
(en)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
Heterocyclic rip1 kinase inhibitors
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
CN117355523A
(en)
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
Polycyclic inhibitors of plasma kallikrein
|
CN117396469A
(en)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
Inhibitors of plasma kallikrein
|
JP2024516073A
(en)
|
2021-03-17 |
2024-04-12 |
武田薬品工業株式会社 |
Heteroaryl inhibitors of plasma kallikrein
|
EP4308227A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Imidazopyridinyl inhibitors of plasma kallikrein
|
EP4308228A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2023183377A1
(en)
|
2022-03-23 |
2023-09-28 |
Rigel Pharmaceuticals, Inc. |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
WO2023192479A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
CN114504550B
(en)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
Eye gel containing metronidazole and preparation method thereof
|